AdultPediatricDosage Forms & Strengths transdermal patch 3.9mg/day Overactive Bladder Indicated for symptom relief in uninhibited neurogenic or reflex neurogenic bladder (urge incontinence, frequency and urgency) Apply 1 patch (releases 3.9 mg/day) twice/week (ie, q3-4 days) Rotate application sites; need not be removed during bathing, swimming, exercising, or sleepingSafety and efficacy not establishedInteraction CheckerEnter a drug name and oxybutynin transdermalNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (0)Serious - Use Alternative (3)lonafarniboxybutynin transdermal will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Closely monitor for arrhythmias and events (eg, syncope, heart palpitations) since lonafarnib effect on QT interval is unknown.pramlintidepramlintide, oxybutynin transdermal. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility.secretinoxybutynin transdermal decreases effects of secretin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Concomitant use of anticholinergic drugs may cause a hyporesponse to stimulation testing with secretin. Discontinue anticholinergic drugs at least 5 half-lives before administering secretin.Monitor Closely (108)abobotulinumtoxinAabobotulinumtoxinA increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.aclidiniumoxybutynin transdermal and aclidinium both decrease cholinergic effects/transmission. Use Caution/Monitor.amantadineoxybutynin transdermal, amantadine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Potential for increased anticholinergic adverse effects.amitriptylineoxybutynin transdermal and amitriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.amoxapineoxybutynin transdermal and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.anticholinergic/sedative combosanticholinergic/sedative combos and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.aripiprazoleoxybutynin transdermal decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin transdermal decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.aripiprazole increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.atracuriumatracurium and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.atropineatropine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.atropine IV/IMatropine IV/IM and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.avapritiniboxybutynin transdermal will increase the level or effect of avapritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.axitiniboxybutynin transdermal increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.belladonna alkaloidsbelladonna alkaloids and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.belladonna and opiumbelladonna and opium and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.benperidoloxybutynin transdermal decreases levels of benperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin transdermal decreases levels of benperidol by pharmacodynamic antagonism. Use Caution/Monitor.benperidol increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.benztropinebenztropine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use. bethanecholbethanechol increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.carbacholcarbachol increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.cevimelinecevimeline increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlorpromazineoxybutynin transdermal decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin transdermal decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.chlorpromazine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.cisatracuriumcisatracurium and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.clomipramineoxybutynin transdermal and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.clozapineoxybutynin transdermal decreases levels of clozapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin transdermal decreases levels of clozapine by pharmacodynamic antagonism. Use Caution/Monitor.clozapine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.cyclizinecyclizine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.cyclobenzaprinecyclobenzaprine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.darifenacindarifenacin and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.desipramineoxybutynin transdermal and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.dicyclominedicyclomine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.diphenhydraminediphenhydramine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.donepezildonepezil increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.donepezil transdermaldonepezil transdermal, oxybutynin transdermal. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.dosulepinoxybutynin transdermal and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.doxepinoxybutynin transdermal and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.droperidoloxybutynin transdermal decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin transdermal decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.droperidol increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.echothiophate iodideechothiophate iodide increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.fesoterodinefesoterodine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.finerenoneoxybutynin transdermal will increase the level or effect of finerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or weak CYP3A4 inhibitors. Adjust finererone dosage as needed.flavoxateflavoxate and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.flibanserinoxybutynin transdermal will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.fluphenazineoxybutynin transdermal decreases levels of fluphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin transdermal decreases levels of fluphenazine by pharmacodynamic antagonism. Use Caution/Monitor.fluphenazine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.galantaminegalantamine increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.glycopyrrolateglycopyrrolate and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.glycopyrrolate inhaledglycopyrrolate inhaled and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.haloperidoloxybutynin transdermal decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin transdermal decreases effects of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor.haloperidol increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.henbanehenbane and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.homatropinehomatropine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.huperzine Ahuperzine A increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.hyoscyaminehyoscyamine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.hyoscyamine sprayhyoscyamine spray and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.iloperidoneoxybutynin transdermal decreases levels of iloperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin transdermal decreases levels of iloperidone by pharmacodynamic antagonism. Use Caution/Monitor.iloperidone increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.imipramineoxybutynin transdermal and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.ipratropiumipratropium and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.isavuconazonium sulfateoxybutynin transdermal will increase the level or effect of isavuconazonium sulfate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.ivacaftoroxybutynin transdermal increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor when coadministered with weak CYP3A4 inhibitors .lemborexantoxybutynin transdermal will increase the level or effect of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Lower nightly dose of lemborexant recommended if coadministered with weak CYP3A4 inhibitors. See drug monograph for specific dosage modification.levodopaoxybutynin transdermal decreases effects of levodopa by pharmacodynamic antagonism. Use Caution/Monitor.lofepramineoxybutynin transdermal and lofepramine both decrease cholinergic effects/transmission. Use Caution/Monitor.lomitapideoxybutynin transdermal increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day.loxapineoxybutynin transdermal decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin transdermal decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor.loxapine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.loxapine inhaledoxybutynin transdermal decreases levels of loxapine inhaled by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin transdermal decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor.loxapine inhaled increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.maprotilineoxybutynin transdermal and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.meclizinemeclizine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.methscopolaminemethscopolamine and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.metoclopramideoxybutynin transdermal decreases effects of metoclopramide by pharmacodynamic antagonism. Use Caution/Monitor. May antagonize prokinetic effects.midazolam intranasaloxybutynin transdermal will increase the level or effect of midazolam intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of mild CYP3A4 inhibitors with midazolam intranasal may cause higher midazolam systemic exposure, which may prolong sedation.neostigmineneostigmine increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.nitrofurantoinoxybutynin transdermal increases levels of nitrofurantoin by unspecified interaction mechanism. Use Caution/Monitor.nortriptylineoxybutynin transdermal and nortriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.olanzapineoxybutynin transdermal decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin transdermal decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.olanzapine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.onabotulinumtoxinAonabotulinumtoxinA and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.orphenadrineoxybutynin transdermal and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.oxybutyninoxybutynin and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.paliperidoneoxybutynin transdermal decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin transdermal decreases levels of paliperidone by pharmacodynamic antagonism. Use Caution/Monitor.paliperidone increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.pancuroniumoxybutynin transdermal and pancuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.perphenazineoxybutynin transdermal decreases levels of perphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin transdermal decreases levels of perphenazine by pharmacodynamic antagonism. Use Caution/Monitor.perphenazine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.physostigminephysostigmine increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.pilocarpinepilocarpine increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.pimozideoxybutynin transdermal decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin transdermal decreases levels of pimozide by pharmacodynamic antagonism. Use Caution/Monitor.pimozide increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.pralidoximeoxybutynin transdermal and pralidoxime both decrease cholinergic effects/transmission. Use Caution/Monitor.prochlorperazineoxybutynin transdermal decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin transdermal decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.promethazineoxybutynin transdermal decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin transdermal decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.promethazine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.propanthelineoxybutynin transdermal and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.protriptylineoxybutynin transdermal and protriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.pyridostigminepyridostigmine increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.quetiapineoxybutynin transdermal decreases levels of quetiapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin transdermal decreases levels of quetiapine by pharmacodynamic antagonism. Use Caution/Monitor.quetiapine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.rapacuroniumoxybutynin transdermal and rapacuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.ribociclibribociclib will increase the level or effect of oxybutynin transdermal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.rimantadineoxybutynin transdermal, rimantadine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Enhanced CNS side effects.risperidoneoxybutynin transdermal decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin transdermal decreases levels of risperidone by pharmacodynamic antagonism. Use Caution/Monitor.risperidone increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.rivastigminerivastigmine increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.rocuroniumoxybutynin transdermal and rocuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.scopolamineoxybutynin transdermal and scopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor.solifenacinoxybutynin transdermal and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.succinylcholinesuccinylcholine increases and oxybutynin transdermal decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.tazemetostatoxybutynin transdermal will increase the level or effect of tazemetostat by affecting